PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)
this morning announced the launch of a medicinal cannabis division, advancing
PreveCeutical’s vision of becoming a global preventive healthcare company. The
cannabis division’s responsibilities include bringing various high-quality,
medicinal cannabis-based products to market and managing the company’s nasal
delivery Sol-gel research program as well as any resulting formulations. The
cannabis division’s products will include transdermal patches, topical creams,
capsules and other methods of administering medicinal cannabis. “The opening of
the cannabis division at this crucial moment is very exciting and continues to
move the company in an important direction. With Canada’s upcoming legalization
of recreational cannabis on October 17, 2018, and the reduction of stigma surrounding
cannabis products, PreveCeutical sees a potential void in the medicinal
cannabis sector as many companies begin to move to recreational market to
accommodate demand. This market shift will provide PreveCeutical with the
opportunity to focus on the healthcare sector and supply the increasing demand
for effective and tailored cannabis-based therapies,” PreveCeutical Medical
chairman, president and CEO Stephen Van Deventer stated in the news release.
To view the full press release, visit http://ibn.fm/NZGGt
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops
innovative options for preventive and curative therapies utilizing organic and
nature identical products. PreveCeutical aims to be a leader in preventive
health sciences and currently has five research and development programs,
including: dual gene therapy for curative and prevention therapies for diabetes
and obesity; the Program; Nature Identical™ peptides for treatment of various
ailments; non-addictive analgesic peptides as a replacement to the highly
addictive analgesics such as morphine, fentanyl and oxycodone; and a
therapeutic product for treating athletes who suffer from concussions (mild
traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster.
CELLB9® is an oral solution containing polarized and potentiated essential
minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion
venom. This product is available on the company’s website. For more information
about PreveCeutical, please visit www.PreveCeutical.com
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment